Another study offered similar evidence by showing that a combination of low doses of PPARα (fenofibrate) and PPARγ (rosiglitazone) activators reduced the hypertension development in the model of Ang II–infused Sprague–Dawley rats (Ciuceis et al. 2007). Here, PPARA is linked to hypertensive disorder.